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Background: Ku80 is crucially implicated in DNA repair, apoptosis, and chemoresistance. In this study, we aimed to
assess the expression of Ku80 in clinical lung adenocarcinoma specimens, and investigate its role in the regulation
of cisplatin sensitivity in cisplatin resistant human lung adenocarcinoma cells A549/DDP.
Methods: Tumor specimens and medical records of 106 patients with operable lung adenocarcinoma were
obtained from 1998 to 2003. Ku80 mRNA and protein levels of the tumor samples, cultured human lung
adenocarcinoma cells A549 cells and their cisplatin resistant variant A549/DDP cells were examined by reverse
transcription PCR and western blot analysis. Ku80-specific siRNA or control scramble siRNA was transfected into
A549/DDP cells, then cell sensitivity to cisplatin was examined by 3-(4,5-dimethylthia-zol-2-yl)-2,5-
diphenyltetrazolium bromide assay and apoptosis was assessed by flow cytometric analysis. In addition, the levels
of cleaved caspase-3 and cleaved PARP in the treated cells were detected by western blot analysis.
Results: Total 83.3% (20/24) cisplatin-resistant tumors had high Ku80 expression, while 8.3% (4/48) cisplatin-sensitive
tumors had high Ku80 expression (p < 0.01). Univariate analysis indicated that overall survival and progression-free
survival were significantly better in lung adenocarcinoma patients with low vs. high Ku80 expression level (p < 0.01).
Ku80 mRNA and protein expression levels were significantly increased in A549/DDP cells compared to parental
A549 cells. siRNA mediated knockdown of Ku80 resensitized A549/DDP cells to cisplatin-induced apoptosis.
Conclusions: Ku80 expression level could predict the outcome and the sensitivity to cisplatin-based chemotherapy
in patients with lung adenocarcima. Ku80-siRNA could be utilized as a therapeutic strategy to resensitize
nonresponders to cisplatin.
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Lung cancer is the leading cause of cancer death in
males and the second-leading cause of cancer deaths in
females worldwide [1]. In the past decades, lung adeno-
carcinoma, one histological subtype of non-small cell
lung cancer (NSCLC), has become the most common
histologic type among all lung cancers diagnosed [2].
Platinum based combination chemotherapy is the stand-
ard chemotherapy for NSCLC, and cisplatin is widely
used for the treatment of lung cancer [3]. However, indi-
viduals respond to chemotherapy differently and the effi-
cacy of cisplatin treatment is often impaired by the* Correspondence: doctorzhangj@sina.com
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reproduction in any medium, provided the oremergence of resistance to this drug [4]. Therefore, elu-
cidating the mechanism underlying the development of
chemoresistance would promote our understanding of
lung cancer progression and treatment failure.
The heterodimeric Ku antigen, which acts as a mo-
lecular detector of DNA double strands, consists of two
subunits of 70 kDa (Ku70) and 80 kDa (Ku80 or Ku86)
and activate DNA protein kinase (DNA-PK) by binding
directly to free DNA termini in a non-sequence-specific
manner [5,6]. Expression of Ku was shown to be upregu-
lated in human aggressive breast cancer, lung cancer and
bladder cancer [7-10]. Moreover, Ku is involved in the
resistance of ovarian cancer and leukemic cells to cis-
platin [11-13]. However, little is known about the ex-
pression of Ku80 and its role in cisplatin resistance in
human lung adenocarcinoma. Therefore, in this study,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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noma specimens, and found that Ku80 was markedly
overexpressed in primary human lung adenocarcinoma
and high Ku80 expression was associated with poor cli-
nical outcomes and resistance to cisplatin-based chemo-
therapy. siRNA mediated knockdown of Ku80 enhanced
the proapoptotic effects of chemotherapy on cisplatin-
resistant lung adenocarcinoma cells A549/DDP.
Materials and methods
Patients and samples
Tumor samples from resection specimens were collected
from patients with primary lung adenocarcinomas be-
tween January 1998 and July 2003, who underwent ge-
neral thoracic surgery at the Second Hospital of Jilin
University. The study was approved by the Ethics Com-
mittee of the Second Hospital of Jilin University (Chang-
chun, China) and all patients gave informed consent. All
excised tissues were frozen immediately in liquid nitro-
gen and then stored at −80 °C. Patient medical records
were reviewed to obtain tumor staging, pathology, and
survival information. The pathologic diagnosis of the
resected tumors was based on the World Health
Organization histological classification of tumors of the
lung [14]. The post-operative disease stage was per-
formed according to the International Union against
Cancer's tumor-node-metastasis (TNM) classification
[15]. All 106 patients underwent radical surgery. Patients
with preoperative chemotherapy or radiotherapy treat-
ment or with evidence of other malignancies were
excluded. No patients received gene-targeted therapy
during the follow-up period. Eighty-six patients received
appropriate chemotherapy or radiotherapy as needed.
Among them, 66 patients received more than three
cycles of cisplatin-based chemotherapy. Platinum sensi-
tivity, as a measure of treatment response, was defined
as no disease progression or relapse during or within
6 months after chemotherapy [16]. The median clinical
follow-up time was 38.5 months (range: 7–60 months).
Overall survival was defined as the time from the diag-
nosis to death from any cause. Progression-free survival
was defined as the time from the diagnosis to progres-
sive disease, relapse or death from any cause, whichever
occurred first. Cases lost to follow-up and deaths caused
by conditions other than lung adenocarcinoma were
regarded as censored data in the survival analysis.
Immunohistochemistry
Paraffin-embedded tissue sections of primary lung
adenocarcinoma and the adjacent normal lung tissues
were used for immunohistochemical studies. Sections
from paraffin-embedded tumors were incubated over-
night with mouse anti-human Ku80 monoclonal anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA) at1:500 dilution, followed by incubation with goat anti-
mouse secondary antibody (Pierce, Rockford, IL, USA).
Immunohistochemical evaluation was performed by two
pathologists without knowledge of the clinical and
pathological characteristics of these patients. The ave-
rage optical density and the average positive area ratio
from five nonoverlapping, randomly selected fields per
section with high-magnification (400×) were examined
and counted. Average optical density reflected the posi-
tive intensity of area expressing Ku80 protein and
equaled to average optical density of positive stained
area. The positive area ratio reflected the scope of area
with positive Ku80 expression and was calculated as (the
total positive area per unit area/the total cells per unit
area) × 100%. In the case of nuclear staining of Ku80, the
percentage of positive cells was determined and divided
into three groups: nuclear staining in less than 25% of
cells (weak), nuclear staining in ≥25% of tumor cells and
≤50% of tumor cells (low) or nuclear staining in >50% of
tumor cells (high).
Cell lines and transfection
The human lung adenocarcinoma cell line A549 and its
cisplatin-resistant variant A549/DDP were cultured as
previously described [17]. Small interfering RNA
(siRNA) sequences targeting human Ku80 and a non-
target sequence were constructed by Genechem (Gene-
chem, Shanghai, China). The Ku80 siRNA (si-Ku80)
were designed with the following sequences as previously
described [18,19]: sense 5'GGAUGGAGUUACUCUGA
UUTT3', antisense 5'AAUCAGAGUAACUCCAUCCTT3'.
The non-target siRNA (Scramble) sequences were as
follows: sense 5'UUCUCCGAACGUGUCACGUTT3',
antisense 5'ACGUGACACGUUCGGAGAATT3'. Trans-
fection with siRNA was performed using LipofectA-
MINE 2000 (Invitrogen, Carlsbad, CA) in accordance
with the manufacturer’s protocol. Briefly, A549/DDP
cells were seeded into six-well plates at the density
of 2 × 105 cells/well, and the cells grew to 50-70% con-
fluent in the next day. Then the cells were transfected
with 100 pmol si-Ku80 or si-Scramble by using 10 μl
LipofectAMINE 2000 (Invitrogen). For the 3-(4,5-
dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assays and flow cytometry analysis, the transfected cells
were treated with cisplatin for 24 h. The cells were
harvested 48 h after transfection.
Cell viability assay
The MTT staining kit (Sigma-Aldrich, St. Louis, MO)
was used to determine cell viability. A549/DDP cells
were plated into 96-well plates (1 × 104/well) for 24 h
and then treated with various concentrations of cisplatin
for 24 h. Next the cells were treated with 0.5 g/l MTT
solution for 4 h. The medium was removed, and 100 μl
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mazan dye crystals were solubilized for 15 min and the
optical density was measured using a microplate reader
(Bio-Rad, Richmond, CA) at a wavelength of 570 nm.
All experiments were performed in triplicate.
Flow cytometry analysis of apoptosis
After treatment for the defined time, A549/DDP cells
were trypsinized and collected, washed, and stained
using the Annexin-V-FITC Apoptosis Detection Kit
(Beyotime, Shanghai, China). The samples were sub-
jected to a FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ). Annexin-V-FITC(−)/PI(−) was used
to indicate cells that had survived, Annexin-V-FITC
(+)/PI(−) was used to indicate cells in the early stage of
apoptosis, and Annexin-V-FITC(+)/PI(+) was used to in-
dicate cells in the late stage of apoptosis or necrosis.
Reverse-transcriptase PCR analysis
Total RNA were isolated from cultured cells or tumor
samples by using Trizol (Invitrogen, USA) according to
the manufacturer’s instruction. Complementary DNA
(cDNA) was synthesized by reverse transcription of 1 μg
RNA samples with SuperScript pre-amplification system
(Promega, Madison, MI). One tenth of the reverse tran-
scribed RNA was used in PCR reaction. The primer
sequences were as follows: GAPDH forward 50 - GAAG
GTGAAGGTCGGAGTC-30 and reverse 50- GAAGAT
GGTGATGGGATTTC0 (product 300 bp); Ku80 forward
50-ACGATTTGGTACAGATGGCACT−30 and reverse
50-GCTCCTTGAAGACGCACAGTTT −30 (product 497 bp).
RT-PCR products were separated by electrophoresis on
1.5% agarose gel containing ethidium bromide.
Western blot analysis
Total protein was isolated from culture cells or tumor
samples and subjected to western blotting analysis as
previously described [20]. Equal amounts of protein
(40 μg) as determined by the Protein Assay Kit (Bio-Rad,
Hercules, CA) was separated by 12% PAGE and trans-
ferred onto nitrocellulose membranes (Millipore, Bed-
ford, MA). The membranes were blocked with 5%
nonfat milk diluted in buffer (10 mM Tris–HCl,
100 mM NaCl and 0.1% Tween 20) for 1 h at room
temperature. The membranes were then incubated with
primary antibodies at 1: 1000 dilution for Ku80, cleaved-
PARP, cleaved-Caspase 3, or β-actin (Abcam, MA, USA),
followed by incubation with Horseradish peroxidase-
conjugated secondary antibodies (Thermo, Waltham,
USA) at 1: 2000 dilution for 1 h at room temperature.
The protein bands were detected by an enhanced chemi-
luminescene kit (Pierce, Rockford, USA). Protein levels
were quantified by densitometry using Quantity One
software (Bio-Rad).Statistical analysis
The data were presented as mean ± standard deviation.
All statistical analysis was performed using SPSS.17.0
software (SPSS, Chicago, IL, USA). The paired-samples
Wilcoxon signed rank test was used to compare the ex-
pression of Ku80 between tumor and adjacent normal
tissues. A 2-fold difference between control and test was
considered the cut-off point to define high or low ex-
pression. Comparisons between treatments were made
using one-way ANOVA for multiple group compari-
sons and differences between treatments were exam-
ined with a Tukey test. The correlation between Ku80
expression and clinic pathologic features was examined
using the Pearson’s Chi-squared test. Overall survival
and progression-free survival were calculated using the
Kaplan–Meier method and log-rank tests. A 2-tailed P
value of less than 0.05 was defined as statistical
significance.
Results
Ku80 is overexpressed in lung adenocarcinoma tissues
First we examined mRNA and protein expression of
Ku80 in 106 pairs of snap-frozen lung adenocarcinoma
and adjacent nonmalignant lung tissues. Representa-
tive data from four tumor and four non-tumor lung
tissues were shown in Figure 1. As shown in Table 1,
73.8% (78/106) lung adenocarcinoma tissues showed
high Ku80 mRNA expression (Figure 1A and C), and
78.3% (83/106) lung adenocarcinoma tissues showed
high Ku80 protein expression (Figure 1B and D). By
using a cutoff point of 2, we found that expression of
Ku80 mRNA and protein was significantly reduced in
lung adenocarcinoma vs. the non-tumor tissues (P =
0.006 and P = 0.005, respectively). A Spearman bivariate
correlation showed a positive correlation (r = 0.97, P <
0.01) between the mRNA and protein levels of Ku80
(data not shown). Immunohistochemistry analysis demon-
strated that Ku80 protein was expressed at low level in
normal human lung tissues (Figure 2A) but at higher level
in human adenocarcinoma tissues (Figure 2B and C)
shown as nuclear brown-yellow granular staining.
Ku80 expression level is correlated with poor survival and
resistance to cisplatin chemotherapy in lung
adenocarcinoma patients
We next addressed the relationship between Ku80 ex-
pression and clinicopathologic parameters of lung
adenocarcinoma patients. As shown in Table 1, Ku80
overexpression showed significant correlations with
lymph node metastasis status (P = 0.01) and TNM stage
(P <0.05), but no correlation was noticed between Ku80
expression level and age, gender, smoking status or
tumor grade. Analysis using the Kaplan–Meier method
indicated that lung adenocarcinoma patients with high
Figure 1 Ku80 mRNA and protein expression in human lung adenocarcinoma tumor tissues. (A) Ku80 mRNA level was detected by
RT-PCR in tissue samples from lung adenocarcinoma tumor (T) and corresponding nontumorous (N) lung tissues. Shown were results from 4
representative paired-samples. (B) Quantitative data from A. (C) Ku80 protein level was detected by western blot in tissue samples from lung
adenocarcinoma tumor (T) and corresponding nontumorous (N) lung tissues. Shown were results from 4 representative western paired-samples.
(D) Quantitative data from C. *p < 0.01 compared to the normal tissues using Wilcoxon signed rank test.
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vival compared to those with low Ku80 level (20.17 ver-
sus 57 months, P < 0.001 by the log-rank test;
Figure 3A). Moreover, the progress-free interval was sig-
nificantly higher in the low Ku80 level group than in the
high Ku80 level group (P < 0.0001, Figure 3B). TakenTable 1 Association of Ku80 expression with clinical characte
Characteristics patients (n = 106) Ku80 mRNA level
Low (n = 28)
Age at diagnosis of lung AC






Former and current smokers 74(69.8) 17(60.7)
Tumor grade
Well differentiated 36(34.0) 15(53.6)
Moderately differentiated 32(30.2) 7(25.0)







III 26(24.5) 5(17.9)together, these data demonstrate that Ku80 is overex-
pressed in primary lung adenocarcinoma compared with
normal lung tissue, and high Ku80 level is associated
with poor survival in lung adenocarcinoma patients.
In addition, as shown in Table 2, in this study
72 patients were treated with at least three cycles ofristics of 106 patients with lung adenocarcinoma
P Ku80 protein level P




















Figure 2 Immunohistochemical staining of Ku80 in lung adenocarcinoma and adjacent nontumor lung tissues. (A) Ku80 staining was
weak in nontumorous lung tissue, (B) low level of expression of Ku80 in lung adenocarcinoma and (C) high level of expression of Ku80 in lung
adenocarcinoma. Ku80 staining was brown and predominantly nuclear in the samples examined. Magnification × 400, scale bar 50 μm.
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platin resistance group (n = 24) and cispaltin sensitivity
group (n = 48) as defined previously [21]. Among these
patients, 83.3% (20/24) cisplatin-resistant tumors showed
high Ku80 expression level, while only 8.33% (4/48)
cisplatin-sensitive tumors showed high Ku80 expression
level. There was significant difference between the two
groups (p < 0.01). These results suggest that Ku80 level isFigure 3 Kaplan–Meier curve of overall survival of lung adenocarcino
analysis of tumor-specific overall survival in all lung adenocarcinoma patien
94.4% for the patients with low Ku80 protein level (n = 23), and 79.8% for p
of progression-free survival according to Ku80 protein level. The progressio
for the patients with low Ku80 protein level (n = 23), and 20.18 ± 1.72 (95%associated with the resistance to cisplatin-based chemo-
therapy in lung adenocarcinoma patients.Knockdown of Ku80 enhances cisplatin-induced apoptosis
of cisplatin-resistant A549/DDP cells
To characterize the role of Ku80 in the cisplatin resis-
tance of lung adenocarcinoma, we examined Ku80ma patients with low and high Ku80 expression. (A) Kaplan–Meier
ts according to Ku80 protein level. The 5-year survival probability was
atients with high Ku80 protein level (n = 83). (B) Kaplan–Meier analysis
n-free survival interval was 45.56 ± 3.85 (95% CI: 37.99-53.12) months
CI: 16.81-23.54) for patients with high Ku80 protein level (n = 83).
Table 2 The therapeutic status for patients with lung
adenocarcinoma after surgery
Stage Number Therapy after surgery
No therapy Chemotherapy Radiotherapy
1-2 cycles > 2 cycles
I 23 20 0 0 3
II 57 0 12 40 27
III 26 0 0 26 21
total 106 20 12 66 51
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cells. Up-regulation of Ku80 at both mRNA and protein
levels was detected in the cisplatin-resistant A549/DDP
cells (Figure 4A and B), suggesting that increased
expression of Ku80 promotes cisplatin resistance.
To further confirm the effects of Ku80 on cisplatin
sensitivity in human lung adenocarcinoma, we used
siRNA to downregulate Ku80 expression in A549/DDP
cells (Figure 5A and B). Cisplatin markedly increased the
viability of si-Ku80 A549/DDP cells, whereas scramble-
siRNA transfected cells were considerably less sensitive
to cisplatin (Figure 5C).
The flow cytometry analysis showed that the apoptosis
ratio was increased in siKu80-A549/DDP cells compared
to scramble-siRNA transfected cells (24.16% vs. 12.15%,
P < 0.05; Figure 5D). Furthermore, western blot analysis
showed that si-Ku80 A549/DDP cells exhibited markedly
increased activation of caspase-3 and cleavage of PARP
in response to cisplatin, compared to scramble-siRNA
transfected cells (Figure 5E and F). Collectively, theseFigure 4 Expression of Ku80 in A549 and A549/DDP cells. (A) RT-PCR a
analysis of Ku80 protein in A549 and A549/DDP cells. (C) Quantification of
level relative to β-actin. Data represented mean ± SD for three replicate exresults suggest that Ku80 protects lung adenocarcinoma
cells against cisplatin-induced apoptosis.
Discussion
Platinum-based chemotherapies show promise in the
treatment of lung cancer but their application has been
limited by drug resistance [4]. Cisplatin, one classic pla-
tinum, has for many years been used as a systematic
chemotherapeutic agent for the treatment of NSCLC
[22]. Therefore, a better understanding of the mecha-
nisms responsible for cisplatin resistance in lung cancer
will improve the efficacy of cisplatin in clinical oncology.
In this study, we demonstrated that Ku80 is specific-
ally up-regulated in lung adenocarcinoma compared to
adjacent normal lung tissues. In addition, we found that
increased Ku80 expression is associated with lymph
node metastasis, TNM stage and tumor response to
cisplatin-based adjuvant therapy, shorter overall and
progression-free survival in patients with lung adenocar-
cinoma. The mechanism of action of cisplatin involves
covalent binding to purine DNA bases, which primarily
leads to cellular apoptosis. An increasing number of
studies suggest that increased DNA repair capacity plays
a critical role in cellular cisplatin resistance in many can-
cers including lung cancer [23,24]. Ku is known for its
crucial role in DNA repair and may contribute to cis-
platin resistance in lung adenocarcinoma. It has been
shown that a rodent Ku80 knockout cell line exhibited
hypersensitivity to cisplatin and reconstitution of human
Ku80 in this cell line led to enhanced resistance to
cisplatin [13].nalysis of Ku80 mRNA in A549 and A549/DDP cells. (B) Western blot
Ku80 mRNA level relative to GAPDH. (D) Quantification of Ku80 protein
periments. *P < 0.05.
Figure 5 Knockdown of Ku80 enhances cisplatin-induced growth inhibition and apoptosis in A549/DDP cells. (A) RT-PCR analysis of Ku80
mRNA level in A549/DDP cells transfected with Ku80 siRNA (siKu80) or non-target sequence siRNA (Scramble). (B) Western blot analysis of Ku80
protein level in A549/DDP cells transfected with siKu80 or Scramble. (C) A549/DDP cells were transfected with siKu80 or Scramble and then
treated with different concentrations of cisplatin for 24 h. Cell viability was determined by MTT assay. Data represented mean ± SD for three
replicate experiments. (D) A549/DDP cells were transfected with siKu80 or Scramble and then treated with 6 μg/ml cisplatin for 24 h. The cells
were collected and stained with Annexin-V-FITC and PI. Shown were representative images of three independent experiments. (E) A549/DDP cells
were transfected with siKu80 or Scramble and then treated with 6 μg/ml cisplatin for 24 h. The cells were collected and subjected to western
blot analysis for the detection of Ku80, cleaved caspase-3 and cleaved PARP levels. Shown were representative blots of three independent
experiments. (F) Quantification of Ku80, cleaved caspase-3 and cleaved PARP levels as shown in (E). Data were presented as mean ± SD, n = 3.
*P < 0.05.
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cluding telomere maintenance, regulation of specific
gene transcription, regulation of heat shock-induced
responses and apoptosis [25]. In this study, we demon-
strated that siRNA mediated knockdown of Ku80
enhanced cisplatin sensitivity and promoted cisplatin-induced apoptosis as well as the activation of caspase-3
and PARP in cisplatin-resistant A549/DDP cells. Apop-
totic pathways contribute to the cytotoxic action of cis-
platin therapy [26]. Accordingly, the failure to undergo
apoptosis in response to anti-cancer therapy may result
in cancer resistance [27]. Caspase-3 plays a central role
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rily responsible for the cleavage of PARP during cell
death [28]. Cleaved caspase-3 indicates the activty of
caspase-3, while PARP is a well-known substrate of
caspase-3 and cleaved PARP indicates the extent of
apoptosis. To further elucidate the possible mechanisms
for Ku80 in cisplatin resistance, we examined the effects
of Ku80-siRNA on cleaved caspase-3 and cleaved PARP.
We observed that the levels of cleaved caspase-3 and
cleaved PARP proteins were significantly increased in si-
Ku80 transfected cells. Downregulation of Ku80, together
with cisplatin treatment, might promote apoptosis by trig-
gering caspases cascades in apoptotic pathways. However,
further studies are needed to elucidate the mechanisms by
which Ku80 downregulation promotes apoptosis of
chemotherapy resistant cancer cells in vivo and in vitro. Li
et al. reported that Ku80 inactivation resulted in the in-
duction of the tumor suppressor protein p53, which may
contribute to the inhibition of cell growth and induction
of apoptosis [29]. Therefore, it will be interesting to exam-
ine the correlation between Ku80 expression and p53 mu-
tation in lung adenocarcinoma patients.
In summary, our data suggest that Ku80 expression
level could predict the outcome and the sensitivity to
cisplatin-based chemotherapy in patients with lung ade-
nocarcima. Ku80 knockdown increases the sensitivity of
cisplatin resistant human lung adenocarcinoma cells to
cisplatin in vitro. Therefore, Ku80 has the potential to
serve as a biomarker for the prediction of cisplatin re-
sponse and represent a promising target for the combi-
nation of cisplatin-based chemotherapy in patients with
lung adenocarcinoma.
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